Trial Profile
International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biocad
- 13 Apr 2016 New trial record